Challenges and solutions in the regulation of PFAS
On 26 March 2026, more than 100 experts from industry and research as well as representatives of OST and Empa met at the Innovation Park East to discuss the impact of the upcoming PFAS regulations on various industries - especially medical technology. Solutions for the gradual replacement of PFAS were jointly proposed.
Downloads
Introduction: Jens Ulmer, OST; Arne Jaksch, Jaksch Life Science consulting
The implication of PFAS restrictions on medtech industry and patients, Dr. Daniel Delfosse, Swiss Medtech
Actual status of the legal process. Update on the RAC and SEAC feedback, Dr. Martijn Beekman EC, DG, REACH
Best practices for industries: Implications on Design, Supply Chain and Alternative Materials, Peter Pianegonda, Gradical GmbH
Functional principles of fluorpolymer coating and its sustainable replacement, Dr. Dirk Hegemann, EMPA
Monitoring of PFAS substitutions regarding safety and sustainability using newly developed prospective SSbD tools, Dr. Peter Wick, EMPA
Overview and challenges for PFAS quantification, Carmen Ziegler, Metrohm
PFAS regulation in US, Dr. Jaana Pietari
We would like to extend our sincere thanks to our cooperation partners:
Our heartfelt thanks go to our generous sponsors:
